In our practice we continue to see that methyl-B12, when used correctly, is still the single most predictable treatment we have to treat children on the autistic spectrum that gives numerous global benefits at the same time. At follow-up our average number of responses during the initial 1st six week methyl-B12 Initiation Phase is 30 to 45 or more. We have now monitored well over ½ million doses of methyl-B12 using numerous protocols. From these data we can document that over 90% of our patients are able to demonstrate undeniable changes as a result of the shots. Of this Responder Group, approximately 20% have remarkable gains, 20% moderate gains, and the remaining 60% show only mild improvements.

View Full Article

You need to login or register to bookmark/favorite this content.